Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy

Next Previous
Trial Profile

A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab sarotalocan (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Nasopharyngeal cancer; Oropharyngeal cancer; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Biomarker; Registrational
  • Sponsors Rakuten Medical

Most Recent Events

  • 01 Dec 2021 Results assessing the safety, pharmacokinetics and efficacy of RM-1929 photoimmunotherapy in patients with heavily pretreated recurrent head and neck squamous cell carcinoma, published in the Head and Neck.
  • 27 Oct 2021 Results published in the Media Release
  • 27 Oct 2021 According to a Rakuten Medical media release, Data from this study was published in Head and Neck.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top